Article
Real-world performance of Uromonitor® in urothelial bladder cancer detection: a multicentric trial.
BJU international - 1 Dec 2024
Wolff Ingmar, Kravchuk Anton P, Wirtz Ralph M, Schlomm Thorsten, Rabien Anja, Rong Dezhi, Hofbauer Sebastian L, Labonté Flora K, Barski Dimitri, Otto Thomas, Gössl Andreas, Brookman-May Sabine D, Gilfrich Christian P, Ecke Thorsten H, May Matthias
Abstract excerpt
OBJECTIVES: To compare Uromonitor® (U-Monitor Lda, Porto, Portugal), a multitarget DNA assay that detects mutated proto-oncogenes (telomerase reverse transcriptase [TERT], fibroblast growth factor receptor 3 [FGFR-3], Kirsten rat sarcoma viral oncogene homologue [KRAS]), with urine cytology in the urine-based diagnosis of urothelial carcinoma of the bladder (UCB) within a multicentre real-world setting. PATIENTS...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
